...
首页> 外文期刊>Molecular cancer therapeutics >Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.
【24h】

Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.

机译:拮抗剂配体雄激素受体募集核受体共受体抑制剂的结构基础。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Androgen receptor (AR) recruitment of transcriptional corepressors NCoR and SMRT can be enhanced by antagonists such as mifepristone. This study shows that enhanced NCoR binding to the mifepristone-liganded AR is mediated by the NCoR COOH-terminal N1 CoRNR box and that this selectivity is due to charged residues unique to the COOH-terminal CoRNR boxes of NCoR and SMRT. Significantly, these residues are on a helical face adjacent to oppositely charged residues in helix 4 of the AR ligand-binding domain. Mutagenesis of these AR residues in helix 4, as well as mutation of lysine 720 in helix 3 (predicted to interact with the CoRNR box), markedly impaired AR recruitment of NCoR, indicating that N1 CoRNR box binding is being stabilized by these ionic interactions in the AR ligand-binding domain coactivator/corepressor binding site. Finally, results using a helix 12-deleted AR indicate that mifepristone induces allosteric changes in addition to helix 12 displacement that are critical for NCoR binding. These findings show that AR antagonists can enhance corepressor recruitment by stabilizing a distinct antagonist conformation of the AR coactivator/corepressor binding site and support the development of additional antagonists that may be able to further enhance AR recruitment of corepressors.
机译:诸如米非司酮之类的拮抗剂可增强转录共受体NCoR和SMRT的雄激素受体(AR)募集。这项研究表明,增强的NCoR与米非司酮配体的AR结合是由NCoR COOH末端的N1 CoRNR框介导的,并且这种选择性是由于NCoR和SMRT的COOH末端的CoRNR框所特有的带电残基所致。明显地,这些残基在与AR配体结合结构域的螺旋4中带相反电荷的残基相邻的螺旋面上。螺旋4中这些AR残基的诱变,以及螺旋3中赖氨酸720的突变(预计与CoRNR box相互作用),显着削弱了NCoR的AR募集,表明N1 CoRNR box的结合通过这些离子相互作用而得以稳定。 AR配体结合域共激活子/共抑制子结合位点。最后,使用缺失了螺旋12的AR的结果表明,除了对NCoR结合至关重要的螺旋12置换,米非司酮还诱导了变构变化。这些发现表明,AR拮抗剂可以通过稳定AR共激活剂/共受体结合位点的独特拮抗剂构象来增强共受体抑制剂的募集,并支持其他可能进一步增强共受体抑制剂的AR募集的拮抗剂的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号